Roche’s giredestrant shows 30% reduction in breast cancer recurrence in Phase III trial
Roche's giredestrant demonstrated a 30% reduction in breast cancer recurrence or death in the Phase III lidERA trial, positioning...
BioMarin’s Vosoritide Shows 2.33 cm/yr Growth Gain in Hypochondroplasia Trial
BioMarin's vosoritide demonstrated a 2.33 cm/yr growth gain in hypochondroplasia, with statistical significance and arm span improvements in Phase...
NervGen Prepares RESTORE Phase 3 Trial in Chronic Tetraplegia With NVG-291
NervGen advances RESTORE Phase 3 Trial in chronic tetraplegia with NVG-291, a PTP-sigma inhibitor targeting neural repair without approved...
NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Trial
NBTXR3 achieves 57% complete response rate in stage III lung cancer trial, compared to under 5% with current standard...
Quince’s LAM-001 Shows 67-Meter Walk Distance Gain in PH-ILD Patients
Quince's LAM-001 showed a 67-meter walk distance gain in PH-ILD patients on background treprostinil, advancing toward Phase 2b testing...
Alterity’s ATH434 Phase 2 Data Support Advancement in Multiple System Atrophy
ATH434 Phase 2 data show 48% slowing of functional decline in multiple system atrophy, with swallowing improvements supporting Phase...
Obexelimab Reduces IgG4-RD Flare Risk 56% in Phase 3 INDIGO Trial
Phase 3 INDIGO Trial shows obexelimab reduced IgG4-RD flare risk by 56% while lowering steroid burden and adverse events...
Roche to Present Giredestrant Data on Menopausal Subgroups at ASCO 2026
Roche presents giredestrant data on menopausal subgroups at ASCO 2026, revealing efficacy consistency across pre- and post-menopausal breast cancer...
NBTXR3 Shows 57% Complete Response Rate in Stage III Lung Cancer Trial
NBTXR3 achieved a 57% complete response rate in a stage III lung cancer trial, compared to fewer than 5%...
Quince’s LAM-001 Shows Pulmonary Vascular Resistance Reduction in PH-ILD Patients
LAM-001 demonstrated a 33.9% reduction in pulmonary vascular resistance in PH-ILD patients, prompting Quince Therapeutics to advance to Phase...